Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. grew its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 60.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,784 shares of the company’s stock after purchasing an additional 1,420 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Structure Therapeutics were worth $158,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Sandia Investment Management LP acquired a new stake in Structure Therapeutics during the second quarter valued at $39,000. Quarry LP acquired a new position in shares of Structure Therapeutics during the 2nd quarter worth about $79,000. Bank Pictet & Cie Europe AG purchased a new position in Structure Therapeutics in the 3rd quarter valued at about $206,000. Sei Investments Co. acquired a new stake in Structure Therapeutics in the 2nd quarter worth about $212,000. Finally, Mather Group LLC. purchased a new stake in Structure Therapeutics during the 2nd quarter worth approximately $214,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Trading Down 3.4 %

NASDAQ GPCR opened at $39.74 on Tuesday. The stock has a market cap of $2.27 billion, a PE ratio of -52.99 and a beta of -3.22. Structure Therapeutics Inc. has a twelve month low of $26.61 and a twelve month high of $72.16. The stock has a fifty day simple moving average of $39.55 and a 200-day simple moving average of $39.82.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. Research analysts predict that Structure Therapeutics Inc. will post -0.79 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday, September 23rd. JMP Securities dropped their price target on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research report on Friday, August 9th. Finally, Morgan Stanley started coverage on Structure Therapeutics in a research note on Monday, September 23rd. They set an “overweight” rating and a $118.00 price objective on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $86.80.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.